1. Home
  2. AVLN vs MCB Comparison

AVLN vs MCB Comparison

Compare AVLN & MCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$28.73

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Metropolitan Bank Holding Corp.

MCB

Metropolitan Bank Holding Corp.

HOLD

Current Price

$92.26

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVLN
MCB
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2026
2017

Fundamental Metrics

Financial Performance
Metric
AVLN
MCB
Price
$28.73
$92.26
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$98.67
AVG Volume (30 Days)
258.9K
142.6K
Earning Date
N/A
04-21-2026
Dividend Yield
N/A
1.13%
EPS Growth
N/A
11.64
EPS
N/A
4.40
Revenue
N/A
$11,053,000.00
Revenue This Year
N/A
$37.22
Revenue Next Year
N/A
$14.75
P/E Ratio
N/A
$31.89
Revenue Growth
N/A
N/A
52 Week Low
$24.90
$64.66
52 Week High
$33.32
$102.04

Technical Indicators

Market Signals
Indicator
AVLN
MCB
Relative Strength Index (RSI) 43.91 45.07
Support Level $26.68 $86.40
Resistance Level $29.59 $94.35
Average True Range (ATR) 1.99 2.71
MACD 0.19 -0.59
Stochastic Oscillator 61.44 44.29

Price Performance

Historical Comparison
AVLN
MCB

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

Share on Social Networks: